L’azienda, già citata il 17 ottobre scorso con un francobollo “B”, avrà oggi l’obliterazione specifica presso la propria sede, a Sesto Fiorentino (Firenze) ...

SESTO FIORENTINO - In occasione del 65° anniversario della presenza in Italia della Eli Lilly, Poste Italiane attiverà un ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other safe stocks. Hedge funds, known for their sophisticated investment strategies and ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Insieme a loro hanno firmato anche i Comuni di Sesto Fiorentino e Campi Bisenzio, oltre alla Eli Lilly. Un Liceo troppo stretto e un'azienda che vuole espandersiIl Liceo scientifico Enriques ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil Corp. (XOM) and Costco Wholesale Corp. (COST), as well a micro-cap stock ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

But at this point, Eli Lilly is stacking wins, and Novo is running out of room to surprise. Investors will be watching the next data drop closelybecause in the high-stakes obesity drug market ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Shares of Eli Lilly (LLY) have dopped to a price level that has been support. The stage may be set for a reversal or move higher. Next: Access Our New, Shockingly Simple 'Alert System' Shares of ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...